The EPS projection of IDEXX Laboratories, Inc. (NASDAQ:IDXX) for quarter ended 2016-09-30 is $0.58. Last week, the projection for EPS was $0.58 against target of $0.58, a month earlier. While 2-months ago, this projection was $0.58 versus forecast of $0.58a quarter months earlier, posting a deviation of 0%.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted that 18 days earlier, the share price was revised 2 times on upside. In addition, negative revisions were 0.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 0. While in last 120 and 90 days, positive revisions were 4, and 3, correspondingly.
The per-share earnings downgrade for IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the preceding 30 and 120 were 0 and 0. While in 60 and 90 days were 0, and 0, in that order.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) EPS target was $0.58 for the quarter closed 1. It was based on 5 calls. As on 2016-04-29 the EPS was $0.51. The change was $0.05, posting a deviation of 10.87%. The price projections gave a standard deviation of 0.01.
Quarterly Sales Estimates
IDEXX Laboratories, Inc. (NASDAQ:IDXX) sales prediction for the fiscal 2017 stands at $470.28 and the median estimate is at $475.342. Almost 3 analysts gave sales target.
Among this, the highest sales estimate is $481.5 while the lowest target is $454 showing standard deviation of 14.431%.
As many as 3 analysts have positive sales targets revision while 3 reduced sales estimates, posting a deviation of 0%.
Last month, 3 experts have positive sales number revision. Also, 3 research groups lowered the sales projections, posting a deviation of 0%.
A quarter ago, 3 hiked sales target and 3 reduced sales forecast, posting a deviation of 0.613%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...